Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

60.98 +1.32 (+2.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent Inc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
From Catalent, Inc.
Via Business Wire
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
From Catalent, Inc.
Via Business Wire
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Via Benzinga
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities. 
Via Benzinga
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
From Catalent, Inc.
Via Business Wire
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up... 
Via Benzinga
Four Stocks To Watch This Week - Tuesday, Oct. 01
A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning... 
Via Talk Markets
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
From Catalent, Inc.
Via Business Wire
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves. 
Via Benzinga
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Catalent Stockholders Approve Transaction with Novo Holdings
From Catalent, Inc.
Via Business Wire
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. 
Via The Motley Fool
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI. 
Via Benzinga
CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
Via InvestorPlace
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
From Robbins LLP
Via Business Wire
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
From Robbins LLP
Via GlobeNewswire
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead. 
Via The Motley Fool
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late... 
Via Benzinga
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
From Catalent, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.